This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objective: To investigate the extent that baseline cognitive impairment and intake adherence affected the 13-item Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog) intervention response of a medical food in Alzheimer’s Disease (AD) patients. DESIGN/SETTING/PARTICIPANTS /INTERVENTION/MEASUREMENTS: This analysis was performed on data from a proof-of-concept study, consisting of a 12-week, double-blind, randomized, controlled, multicenter trial, […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]
The efficacy of nonpharmacological treatment for dementia-related apathy
Ferrero-Arias, Julio,
Goñi-Imízcoz, Miguel,
González-Bernal, Jerónimo,
Lara-Ortega, Fernando,
da Silva-González, Alvaro,
Díez-Lopez, Mateo
Objective: To determine the usefulness of a formal, structured, nonpharmacological treatment for apathetic dementia patients.; Patients and Methods: A controlled, cross-over, randomized, simple-blind, multicentre clinical trial. A total of 146 institutionalized or day care dementia patients with a stage 1 or 2 Clinical Dementia Rating, with no significant motor or sensory problems, or with rapidly […]
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, Martin,
Veloso, Felix,
Moline, Margaret,
Yardley, Jane,
Brand-Schieber, Elimor,
Bibbiani, Francesco,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing […]
Multifactorial fall prevention for pairs of frail community-dwelling older fallers and their informal caregivers: a dead end for complex interventions in the frailest fallers
Faes, Miriam C.,
Reelick, Miriam F.,
Melis, René J.,
Borm, George F.,
Esselink, Rianne A.,
Rikkert, Marcel G. Olde
Objective: To assess whether a multifactorial fall prevention program was more effective than usual geriatric care in preventing falls and reducing fear of falling in frail community-dwelling older fallers, with and without cognitive impairment, and in alleviating subjective caregiver burden in caregivers.; Design, Setting, and Participants: A randomized, 2 parallel-group, single-blind, multicenter trial conducted in […]
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
de Yebenes, Justo Garcia,
Landwehrmeyer, Bernhard,
Squitieri, Ferdinando,
Reilmann, Ralf,
Rosser, Anne,
Barker, Roger A,
Saft, Carsten,
Magnet, Markus K.,
Sword, Alastair,
Rembratt, Åsa,
Tedroff, Joakim
Background: Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary motor function. We aimed to assess further the […]